Hypersensitivity to darunavir or to any of the excipients.
Darunavir and ritonavir are inhibitors of the cytochrome P450 3A (CYP3A) isoform. Darunavir should not be co-administered with medicinal products that are highly dependent on CYP3A for clearance and for which increased plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). These medicinal products include alfuzosin, astemizole, cisapride, colchicine (in patients with renal and/or hepatic impairment), dronedarone, elbasavir/grazoprevir, the ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine and methylergonovine), lomitapride, lovastatin, lurasidone, midazolam (oral), pimozide, ranolazine, sildenafil (when used for treatment of pulmonary arterial hypertension), simvastatin, terfenadine and triazolam (see Interactions).
Patients taking darunavir should not use products containing rifampicin or St. John's wort because co-administration may result in reduced plasma concentrations of darunavir. This may result in loss of therapeutic effect and development of resistance.